Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

2014 ◽  
Author(s):  
Richard S. Finn ◽  
John P. Crown ◽  
Istvan Lang ◽  
Katalin Boer ◽  
Igor M. Bondarenko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Breast ◽  
Line Treatment ◽  
Cyclin Dependent Kinase ◽  
First Line ◽  
Randomized Phase Ii ◽  
First Line Treatment

scholarly journals Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study

2018 ◽  
Vol 109 (3) ◽  
pp. 803-813 ◽  
Author(s):  
Norikazu Masuda ◽  
Reiki Nishimura ◽  
Masato Takahashi ◽  
Kenichi Inoue ◽  
Shinji Ohno ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Breast ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document